Legal provisions of COM(2005)106 - Amendment of Regulation (EC) No 297/95 on fees payable to the European Medicines Agency - Main contents
Please note
This page contains a limited version of this dossier in the EU Monitor.
dossier | COM(2005)106 - Amendment of Regulation (EC) No 297/95 on fees payable to the European Medicines Agency. |
---|---|
document | COM(2005)106 ![]() |
date | November 14, 2005 |
Article 1
1. | the second paragraph of Article 1 shall be replaced by the following: ‘The amounts of these fees shall be laid down in euro.’; |
2. | Article 3 is amended as follows:
|
3. | Article 4 shall be replaced by the following: ‘Article 4 Medicinal products for human use covered by the procedures laid down in Directive 2001/83/EC A referral fee of EUR 58 000 shall apply where the procedures laid down in Article 30(1) and Article 31 of Directive 2001/83/EC are initiated by the applicant of a marketing authorisation or the holder of an existing marketing authorisation. Where more than one applicant of marketing authorisations or holder of existing marketing authorisations are concerned by the procedures referred to in the first subparagraph, the applicants or holders may be grouped for the purpose of the payment of one single referral fee. If however, the same procedure concerns more than ten different applicants or holders, the fee shall be charged by the application of the abovementioned referral fee.’; |
4. | Article 5 is amended as follows:
|
5. | Article 6 shall be replaced by the following: ‘Article 6 Veterinary medicinal products covered by the procedures laid down in Directive 2001/82/EC A referral fee of EUR 34 800 shall apply where the procedures laid down in Article 34(1) and Article 35 of Directive 2001/82/EC are initiated by the applicant of a marketing authorisation or the holder of an existing marketing authorisation. Where more than one applicant of marketing authorisations or holder of existing marketing authorisations are concerned by the procedures referred to in the first subparagraph, the applicants or holders may be grouped for the purpose of the payment of one single referral fee. If however, the same procedure concerns more than ten different applicants or holders, the fee shall be charged by the application of the abovementioned referral fee.’; |
6. | Article 7 is amended as follows:
|
7. | Article 8 shall be replaced by the following: ‘Article 8 Various Fees The scientific advice fee shall apply where an application is made for scientific advice concerning the conduct of the various tests and trials necessary to demonstrate the quality, safety and efficacy of medicinal products. When it concerns medicinal products for human use, the fee shall be EUR 69 600. When it concerns veterinary medicinal products, the fee shall be EUR 34 800. By derogation from the second subparagraph, a reduced scientific advice fee falling within the range of EUR 17 400 to EUR 52 200 shall apply for certain scientific advice concerning medicinal products for human use. By derogation from the third subparagraph, a reduced scientific advice fee falling within the range of EUR 8 700 to EUR 26 100 shall apply for certain scientific advice concerning veterinary medicinal products. The scientific advice referred to in the fourth and fifth subparagraph shall be included in a list, which shall be drawn up in accordance with Article 11(2). A scientific service fee shall apply where an application is made for any scientific advice or opinion by a scientific Committee, which is not covered by Articles 3 to 7 or by Article 8(1). This includes any evaluation of traditional herbal medicinal products, any opinion on medicinal products for compassionate use, any consultation on ancillary substances, including blood derivatives, incorporated in medical devices, and any evaluation of plasma master files and vaccine antigen master files. When it concerns medicinal products for human use, the fee shall be EUR 232 000. When it concerns veterinary medicinal products, the fee shall be EUR 116 000. Article 3 of this Regulation shall apply to any scientific opinion for the evaluation of medicinal products for human use intended exclusively for markets outside the Community pursuant to Article 58 of Regulation (EC) No 726/2004. By derogation from the second subparagraph, a reduced scientific service fee falling within the range of EUR 2 500 to EUR 200 000 shall apply for certain scientific opinions or services concerning medicinal products for human use. By derogation from the third subparagraph, a reduced scientific service fee falling within the range of EUR 2 500 to EUR 100 000 shall apply for certain scientific opinions or services concerning veterinary medicinal products. The scientific opinions or services referred to in the fifth and sixth subparagraph shall be included in a list, which shall be drawn up in accordance with Article 11(2). A fee falling within the range of EUR 100 to EUR 5 800 shall apply for administrative services where documents or certificates are issued outside the framework of services covered by another fee provided for in this Regulation or where an application is rejected following the conclusion of the administrative validation of the related dossier or where the information required in the case of parallel distribution has to be checked. A classification of the services and fees shall be included in a list, which shall be drawn up in accordance with Article 11(2).’; |
8. | in Article 9 the second paragraph shall be replaced by the following: ‘A total or partial exemption from payment of the fees laid down in this Regulation may be granted, in particular for medicinal products for treating rare diseases or diseases affecting minor animal species or for extension of existing MRL to additional animal species or for medicinal products available for compassionate use. The detailed conditions for the application of the total or partial exemption shall be determined in accordance with Article 11(2). The fee payable for an opinion on a medicinal product for compassionate use shall be deducted from the fee payable for an application for a marketing authorisation of the same medicinal product, where such application is submitted by the same applicant.’; |
9. | Article 10 shall be replaced by the following: ‘Article 10 Due date and deferral of the payment 1. Fees shall be due on the date of the administrative validation of the relevant application unless specific provisions stipulate otherwise. They shall be payable within 45 days of the date of the notification of the administrative validation to the applicant. They shall be paid in euro. The annual fee shall be due on the first and each subsequent anniversary of the notification of the marketing authorisation decision. It shall be payable within 45 days of the due date. The annual fee shall relate to the preceding year. The inspection fee shall be payable within 45 days from the date on which the inspection is carried out. 2. The payment of the fee for an application for a marketing authorisation of a medicinal product to be used in a human pandemic situation shall be deferred until the pandemic situation is duly recognised, either by the World Health Organisation or by the Community in the framework of Decision No 2119/98/EC of the European Parliament and of the Council of 24 September 1998 setting up a network for the epidemiological surveillance and control of communicable diseases in the Community (12). Such deferral shall not exceed five years. 3. Where any fee payable under this Regulation remains unpaid at its due date and without prejudice to the Agency’s capacity to institute legal proceedings conferred on it by Article 71 of Regulation (EC) No 726/2004, the Executive Director may decide not to provide the requested services or to suspend all the services and procedures under way until the fee has been paid, including the relevant interest as provided for in Article 86 of Commission Regulation (EC, Euratom) No 2342/2002 of 23 December 2002 laying down detailed rules for the implementation of Council Regulation (EC, Euratom) No 1605/2002 on the Financial Regulation applicable to the general budget of the European Communities (13). (12) OJ L 268, 3.10.1998, p. 1. Decision as last amended by Regulation (EC) No 1882/2003 (OJ L 284, 31.10.2003, p. 1)." (13) OJ L 357, 31.12.2002, p. 1. Regulation as amended by Regulation (EC, Euratom) No 1261/2005 (OJ L 201, 2.8.2005, p. 3).’;" |
10. | Article 11(2) shall be replaced by the following: ‘2. Without prejudice to the provisions of Regulation (EC) No 726/2004, the Management Board of the Agency may, on a proposal from the Executive Director and following a favourable opinion from the Commission, specify any provision necessary for the application of this Regulation. Those provisions shall be made publicly available.’; |
11. | Article 12 is amended as follows:
|
Article 2 - Transitional period
Article 3 - Entry into force
It shall apply from 20 November 2005.
This Regulation shall be binding in its entirety and directly applicable in all Member States.